Image with SpicyIP logo and the words "Weekly Review"

SpicyIP Weekly Review (October 12-October 18)

/ By / Copyright, Drug Regulation, Patent, Trademark

[This Weekly Review is prepared by Kaustub Boidi. Kaustub is a final-year law student at SVKM’s NMIMS, Hyderabad.] Here’s this week’s roundup of IP developments, from posts on the Kerala High Court’s Ribociclib decision, the Delhi HC’s tiered approach to patent appeals in Esteve Pharmaceuticals, the PABS Annex of the WHO Pandemic Agreement, to key judicial decisions and national and international IP updates. Anything we missed out on? Drop a comment below to let us know! Highlights of the Week

SpicyIP Weekly Review (October 12-October 18) Read More »

SpicyIP Tidbit: Ali on Patents – A Treatise Built for Reading, Citing and Keeping Up

/ By / Patent

Prof. Feroz Ali has launched Ali on Patents (www.aop.onl), a free, online version of the treatise he first published in 2007. In his launch note on linkedin, he says that everything on the site is either his own words or the words of the court, with no AI-written prose in between. The resource is meant for a wide readership: patent lawyers and agents, in-house counsel, examiners, judges, academics, students and inventors, among others. The site has two kinds of pages:

SpicyIP Tidbit: Ali on Patents – A Treatise Built for Reading, Citing and Keeping Up Read More »

Equitable Pandemic Response: Delink Data Access from Benefit Sharing in the PABS Annex

/ By / Patent

Long Post Ahead! In May 2025, the World Health Organization’s member states adopted the Pandemic Agreement. However, until its Pathogen Access and Benefit-Sharing (PABS) Annex is adopted, it cannot be opened for signature. Currently, the talks on the annex remain stuck on one question: should benefit sharing be tied to access to pathogen data? In this post, I argue that this linkage is itself the problem. Drawing on the model proposed by Knowledge Ecology International (KEI) before the Intergovernmental Working

Equitable Pandemic Response: Delink Data Access from Benefit Sharing in the PABS Annex Read More »

Call for Submisisons: Journal of Intellectual Property Laws(JIPL), Volume X (Deadline: 30 November 2026)

/ By / Opportunities, Publication

The Centre for Intellectual Property Rights (CIPR), Institute of Law, Nirma University is inviting submissions for the Journal of Intellectual Property Laws(JIPL), Volume X. The last date for submission is 30 November. For more details, read the call for submissions below:- Call for Submissions: Journal of Intellectual Property Laws(JIPL), Volume X (Deadline: 30 November 2026) About the Organizer Founded in 2007 under the vision of Dr Karsanbhai K. Patel, the Institute of Law, Nirma University seeks to bring newer dimensions

Call for Submisisons: Journal of Intellectual Property Laws(JIPL), Volume X (Deadline: 30 November 2026) Read More »

The Ghost of Section 100’s Past!

/ By / Drug Regulation, Others, Overlaps in IP, Patent

As Halloween approaches, a particular editorial at ET seems spooked by the prospect of lawful and equitable access to medicines! In doing the opposite of what its title suggests, ‘Protect Patients and Patents Smartly’, the editorial piece published on October 15, 2026 is an unfortunate example of legal misinformation and misinterpretation, stuck in the old binary of access versus patent. This published piece runs contrary to years of judicial wisdom, contradicts itself, conflates different legal questions and advocates for a

The Ghost of Section 100’s Past! Read More »

SpicyIP Tidbit: Putting the Cart Before the Horse: A Look into Esteve Pharmaceuticals vs CPD

/ By / Patent

In the August 7 order passed in Esteve Pharmaceuticals S.A. vs Controller of Patents and Designs (2026), the Delhi High Court adopted a tiered approach in examining the grounds for rejecting a patent application. It accepted that the invention “Co-crystals of Tramadol and Coxibs” was novel (differing from the Controller on 2(1)(j)), but it lacked inventive step (upholding the Controller’s objections under 2(1)(ja)). And because it lacked inventive step, the Court did not find examining further under 3(d) and 3(e)

SpicyIP Tidbit: Putting the Cart Before the Horse: A Look into Esteve Pharmaceuticals vs CPD Read More »

SpicyIP Bells & Whistles: IP Events and Opportunities (13.10.2026)

/ By / Courses & Workshops, Opportunities

Welcome back to another week of Bells & Whistles. As always, we’ve rounded up a mix of developments, opportunities, and thoughtful reads from across the IP world along with a Bell of the Week that’s well worth revisiting. Bell of the Week: Who Really Drives Innovation? When we talk about innovation, we often think of businesses, entrepreneurs and the big breakthroughs they bring to the market. Governments, meanwhile, tend to be seen as playing a supporting role — funding research

SpicyIP Bells & Whistles: IP Events and Opportunities (13.10.2026) Read More »

Image with SpicyIP logo and the words "Weekly Review"

SpicyIP Weekly Review (October 5-October 11)

/ By / Copyright, Patent, Trademark

From notable orders of the past week to key national and international IP developments, here’s the latest edition of the SpicyIP Weekly Review. Did we miss anything? Let us know in the comments! Posts this Week The Innovation Brief, NLU Delhi, is inviting blog post submissions on the ‘Impact of the Intersection of Innovation and Access by the EU-India FTA’. The last date to share submissions is October 20, 2026. Interested readers can read the call for submissions below. Case

SpicyIP Weekly Review (October 5-October 11) Read More »

Ribociclib: Access to Medicine Collides with Patent, Price and Policy

/ By / Drug Regulation, Overlaps in IP, Patent

In this co-authored post, Ambika and Rishabh break down the recent Kerala High Court ruling on government use of patented inventions under Section 100 and situate it in the broader context of other Ribociclib patents and pending litigations that will impact the drug’s access; all this, at a time when patent enforcement and drug pricing rules might be changing. The judgment’s epilogue references popular cinema for recall value (see pg 56 here), but the real blockbuster of this story is

Ribociclib: Access to Medicine Collides with Patent, Price and Policy Read More »

Call for Submissions:’Impact of the Intersection of Innovation and Access by the EU-India FTA'(Deadline: October 20, 2026)

/ By / Opportunities

The Innovation Brief, NLU Delhi, is inviting blog post submissions on the ‘Impact of the Intersection of Innovation and Access by the EU-India FTA’. The last date to share submissions is October 20, 2026. Interested readers can read the call for submissions below:- Call for Submissions: ‘Impact of the Intersection of Innovation and Access by the EU-India FTA’. (Deadline: October 20, 2026) About Innovation Brief The Innovation Brief is a student-led platform at National Law University Delhi that seeks to

Call for Submissions:’Impact of the Intersection of Innovation and Access by the EU-India FTA'(Deadline: October 20, 2026) Read More »

Scroll to Top